Study Summary
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of treatment for AML .
Want to learn more about this trial?
Request More InfoInterventions
CB-012DRUG
CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The University of Alabama at Birmingham (UAB) | Birmingham | Alabama | United States |
| Colorado Blood Cancer Institute | Denver | Colorado | United States |
| Moffitt Cancer Center | Tampa | Florida | United States |
| The Blood & Marrow Transplant Group of Georgia (BMTGA) | Atlanta | Georgia | United States |
| Weill Cornell Medical College | New York | New York | United States |
| Memorial Sloan Kettering Cancer Center (MSKCC) | New York | New York | United States |
| TriStar Bone Marrow Transplant, LLC | Nashville | Tennessee | United States |
| MD Anderson Cancer Center | Houston | Texas | United States |
| Fred Hutchinson Cancer Center | Seattle | Washington | United States |
| Medical College of Wisconsin | Milwaukee | Wisconsin | United States |